The US Centers for Medicare and Medicaid Services made some tweaks from earlier proposals, but moved ahead with finalizing 2018 payment rates for diagnostic test services that a key lab industry group calls "fundamentally flawed."
Lab Sector Vs. CMS Battle Heats Up As Medicare Agency Moves Forward With 2018 Rates
Test-makers and labs say the agency is missing large swaths of the market in making its "market-based" lab payment calculation, but CMS stands by its data, and finalized 2018 lab fee schedule rates. Could next steps be in Congress, or the courts?
More from Business
More from Medtech Insight
• By
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.
• By
The US FDA continues to issue early alerts as part of its communications pilot aimed at improving how the agency manages recalls. This time, the agency is notifying users about two separate intravascular catheters.
• By
The US Medicare agency will hold three public meetings in June and July addressing tremor treatment devices and clinical diagnostic lab tests. The first meeting on June 25 will focus on endpoints for Parkinson’s device trials, while subsequent meetings will address payment rates and codes for laboratory tests.